Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
To enable company to be future-ready by tapping potential in CDMO space
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Calibre will enhance the pace of new product development and the breadth of its Custom Development and Manufacturing (CDMO) Service offerings.
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Bourgoin early development hub broadens offerings for oral solid dose formulations
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Subscribe To Our Newsletter & Stay Updated